Carfilzomib
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Carfilzomib: proteasome inhibitor → CMM7 (CMM7)
One-Sentence Summary
Carfilzomib is a proteasome inhibitor marketed in Australia as Kyprolis. The TxGNN model predicts it may be relevant to CMM7 (CMM7), a cutaneous malignant melanoma susceptibility locus, but this rests on the model score alone: no clinical trials and no publications in the data compiled for this report address this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | CMM7 (CMM7) |
| TxGNN Prediction Score | 0.9937 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Carfilzomib is generally understood to be a proteasome inhibitor, and proteasome inhibition can cause proteotoxic stress and apoptosis in cancer cells. This could plausibly affect melanoma cell survival.
CMM7 is, however, a susceptibility locus for cutaneous malignant melanoma rather than a treatable clinical condition in its own right. No trial or publication links carfilzomib to this entity, so the rationale is speculative. The score (0.9937) reflects a model prediction only.
For context, the other predictions in the data are all melanoma subtypes (pediatric leptomeningeal melanoma, epithelioid cell uveal melanoma, vulvar melanoma and melanoma). Only one has any literature: a preclinical study in B16-F1 mouse melanoma cells (PMID 33671902). That study is not a direct study of CMM7, so it does not raise the evidence level for this prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for CMM7.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11229B | Kyprolis | Powder for injection 30 mg | Not recorded in the local data |
The licence is a single-ingredient product and is currently valid.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antineoplastic; proteasome inhibitor (targeted therapy) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI; haematological parameters, liver and renal function are typically monitored for antineoplastic agents |
| Handling Protection | Follow local cytotoxic drug handling requirements; refer to the PI |
Safety Considerations
Drug Interactions: The interaction query completed with 100 recorded interactions. Examples of those rated Major include:
- Oxandrolone, oxymetholone and stanozolol
- Deferiprone
- Samarium (153Sm) lexidronam
- Aminocaproic acid
- Avatrombopag
- Recombinant and human coagulation factors (antihemophilic factor, von Willebrand factor, factor VIIa, factor X)
- Human C1-esterase inhibitor and conestat alfa
Examples rated Moderate include metronidazole, tinidazole, naltrexone, rosuvastatin, simvastatin, palifermin and strontium chloride Sr-89.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for CMM7 is supported only by a model score, with no clinical trials or publications addressing it. CMM7 is a susceptibility locus rather than a defined treatment target, so the evidence level is L5.
To proceed, the following is needed:
- Clarification of which clinical melanoma entity CMM7 represents and whether it is a treatable target
- Mechanism of action data for carfilzomib
- Preclinical studies directly addressing this disease, followed by clinical evidence if results are supportive
- Review of the TGA-approved PI for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.